These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12949426)

  • 21. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 23. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
    Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
    Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 31. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005.
    Chang K; Qin XJ; Zhang HL; Dai B; Zhu Y; Shi GH; Shen YJ; Zhu YY; Ye DW
    Asian J Androl; 2016; 18(3):452-5. PubMed ID: 26323560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Garnick MB
    BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
    [No Abstract]   [Full Text] [Related]  

  • 37. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ; Iversen P; Newling DW
    Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
    Akyol F; Selek U; Ozyigit G; Onal C; Akdogan B; Karabulut E; Ozen H
    J Natl Med Assoc; 2006 Jul; 98(7):1058-61. PubMed ID: 16895273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.